New Drugs in Pediatric Oncology - Where Do We Stand Now - Pitfalls and Hurdles
| Authors | |
|---|---|
| Year of publication | 2015 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Cancer is still leading cause of death in childhood among diseases. Encouraging progress has been made in the treatment of childhood malignancies during 70th till 90th, and maximum tolerated doses (MTD) of chemotherapy plus radiotherapy contributed significantly, together with improvements in supportive care, to improved overall survival. However, about 20% of children will die due to their malignancy and significant proportion of survivors suffers from treatment related toxicities, including secondary malignancies. Thus, there is clearly an unmet need for new drugs to improve survival and reduce treatment-associated toxicities in contemporary pediatric oncology. However, drug development in pediatric oncology is very complex and has specific requirements with regard to the patient population, regulatory background and presents several unique challenges that need addressing. |